抗血管生成的贝伐珠单抗已被广泛应用于多种恶性肿瘤的治疗。但因其受益人群有限及逐渐出现的获得性耐药,也限制了其对患者总生存的改善。迫切需要寻找有效的预测贝伐珠单抗疗效的预测因子指导临床应用。人们在生物标记物、影像学方面进行了大量探索,但目前尚没有一个公认的普遍适用的临床预测指标,仍需要从多角度出发,进行进一步的基础研究及临床研究去发现和验证有效的疗效预测指标。 Anti-angiogenic bevacizumab has been widely used in the treatment of a variety of malignancies. However, their limited beneficiaries and their progressive acquired resistance also limited their overall survival. There is an urgent need to find effective predictors of the efficacy of bevacizumab in guiding clinical practice. There has been a great deal of exploration in biomarkers and radiology. However, there is not yet a universally accepted clinical prediction index that is universally accepted. However, further basic and clinical studies are still needed to find out and validate effective therapies Predictors.